Keros TherapeuticsKROS
KROS
About: Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Employees: 169
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
159% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 29
3% less call options, than puts
Call options by funds: $10.8M | Put options by funds: $11.2M
5% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 40
1% less funds holding
Funds holding: 163 [Q3] → 161 (-2) [Q4]
2.39% less ownership
Funds ownership: 93.1% [Q3] → 90.72% (-2.39%) [Q4]
60% less funds holding in top 10
Funds holding in top 10: 5 [Q3] → 2 (-3) [Q4]
71% less capital invested
Capital invested by funds: $2.03B [Q3] → $582M (-$1.45B) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
5%
upside
Avg. target
$27
86%
upside
High target
$40
181%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
Truist Securities Srikripa Devarakonda 28% 1-year accuracy 9 / 32 met price target | 75%upside $25 | Buy Maintained | 9 Apr 2025 |
Wedbush Yun Zhong 0% 1-year accuracy 0 / 6 met price target | 5%upside $15 | Neutral Reiterated | 1 Apr 2025 |
HC Wainwright & Co. Andrew Fein 31% 1-year accuracy 110 / 352 met price target | 181%upside $40 | Buy Reiterated | 1 Apr 2025 |
Wells Fargo Tiago Fauth 37% 1-year accuracy 10 / 27 met price target | 82%upside $26 | Overweight Maintained | 27 Feb 2025 |
Financial journalist opinion
Based on 6 articles about KROS published over the past 30 days
Positive
Zacks Investment Research
2 weeks ago
KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5%
The stock rallies 18.5% after Keros initiates a strategic review process exploring alternatives, including a potential sale of the business.
Neutral
Benzinga
2 weeks ago
Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan
Keros Therapeutics, Inc.‘s KROS board of directors initiated a formal review process on Thursday to evaluate strategic alternatives, including a sale.
Neutral
Benzinga
2 weeks ago
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump
U.S. stocks traded lower midway through trading, with the Dow Jones index dipping more than 4% on Thursday.
Negative
Reuters
2 weeks ago
Keros Therapeutics adopts 'poison pill' plan
Keros Therapeutics said on Thursday its board had authorized a stockholder rights plan, also known as a "poison pill", in response to rapid accumulations of the company's stock by some investors.
Neutral
GlobeNewsWire
2 weeks ago
Keros Therapeutics Announces Review of Strategic Alternatives
LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that its Board of Directors (the “Board”) has determined to initiate a formal review process to evaluate strategic alternatives to maximize stockholder value for the Company. In connection with this determination, the Board has authorized the formation of a committee, consisting of independent and disinterested directors, to oversee the process (the “Strategic Committee”) and make a recommendation to the full Board. The Strategic Committee, with the assistance of outside financial and legal advisors, intends to consider a comprehensive range of strategic alternatives, including but not limited to a sale of the company or other business combination transaction, continued investment in the Company's pipeline, and/or return of excess capital to stockholders.
Neutral
GlobeNewsWire
4 weeks ago
Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers
LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced initial topline results from the Phase 1 clinical trial of KER-065 in healthy volunteers. Topline results from this ongoing trial are through the multiple ascending dose (“MAD”) treatment period (Day 85).
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Think Keros Therapeutics (KROS) Could Surge 156.99%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 157% in Keros Therapeutics (KROS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade
The mean of analysts' price targets for Keros Therapeutics (KROS) points to a 153.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
GlobeNewsWire
1 month ago
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate at the following healthcare conferences:
Negative
Zacks Investment Research
2 months ago
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to loss of $1.34 per share a year ago.
Charts implemented using Lightweight Charts™